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Abstract
Silymarin prevents liver disease in many experimental rodent models, and is the most popular botanical medicine
consumed by patients with hepatitis C. Silibinin is a major component of silymarin, consisting of the flavonolignans silybin A
and silybin B, which are insoluble in aqueous solution. A chemically modified and soluble version of silibinin, SIL, has been
shown to potently reduce hepatitis C virus (HCV) RNA levels in vivo when administered intravenously. Silymarin and silibinin
inhibit HCV infection in cell culture by targeting multiple steps in the virus lifecycle. We tested the hepatoprotective profiles
of SIL and silibinin in assays that measure antiviral and anti-inflammatory functions. Both mixtures inhibited fusion of HCV
pseudoparticles (HCVpp) with fluorescent liposomes in a dose-dependent fashion. SIL inhibited 5 clinical genotype 1b
isolates of NS5B RNA dependent RNA polymerase (RdRp) activity better than silibinin, with IC50 values of 40–85 mM. The
enhanced activity of SIL may have been in part due to inhibition of NS5B binding to RNA templates. However, inhibition of
the RdRps by both mixtures plateaued at 43–73%, suggesting that the products are poor overall inhibitors of RdRp. Silibinin
did not inhibit HCV replication in subgenomic genotype 1b or 2a replicon cell lines, but it did inhibit JFH-1 infection. In
contrast, SIL inhibited 1b but not 2a subgenomic replicons and also inhibited JFH-1 infection. Both mixtures inhibited
production of progeny virus particles. Silibinin but not SIL inhibited NF-kB- and IFN-B-dependent transcription in Huh7 cells.
However, both mixtures inhibited T cell proliferation to similar degrees. These data underscore the differences and
similarities between the intravenous and oral formulations of silibinin, which could influence the clinical effects of this
mixture on patients with chronic liver diseases.
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Introduction
Globally, HCV infects an estimated 150 million people, and
causes an estimated 376,000 deaths per year due to complications of
end stage liver disease [1]. In the United States, about 1.8% of the
general population (,4 million persons) is infected. Pegylated
interferon (IFN) plus ribavirin therapy is now the standard of care
[2,3,4]. However, 50% of treated patients still do not clear viremia
when treated with peg-IFN plus ribavirin. Moreover, IFN therapy is
costly, has significant side effects, and many patients are ineligible for
therapy. Thus, many patients seek complementary and alternative
medicine (CAM)-based strategies to improve their health.
Silymarin, which consists primarily of seven flavonolignans [5],
is an extract of the seeds of milk thistle Silybum marianum, and is
the most common botanical consumed by patients with chronic
hepatitis C [6]. Many effects of silymarin have been described in
vitro and in animal models, all of which likely contribute to its
hepatoprotective effects. These include anti-oxidant, anti-inflam-
matory, anti-proliferative, anti-fibrotic, anti-viral and immuno-
modulatory effects [7]. The description of these effects in modern
journals, in addition to descriptions in ancient medical texts and
oral history have likely influenced the millions of people
throughout the world who consume silymarin, despite the fact
that clinical trials have shown variable clinical efficacy [8,9,10],
and mechanisms of action in chronic hepatitis C have only begun
to be characterized.
We have shown that silymarin and a major component of the
extract, silibinin, which is composed of silybin A and silybin B [5],
inhibits HCV replication, HCV-induced oxidative stress, NF-kB
dependent transcription, and T cell proliferation and inflamma-
tory cytokine production[11,12,13]. Silymarin also inhibits NS5B
RNA dependent RNA polymerase (RdRp) activity in in vitro assays
using purified recombinant polymerase. However, polymerase
inhibition is variable [14] [11,15].
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Silibinin is insoluble in aqueous solution. Moreover, silymarin
and silibinin are typically administered orally, which limits the
efficacy of the natural product because of its poor absorption and
short half-life in the body. Indeed, plasma levels of silymarin-
derived flavonolignans peak within 1–2 hours of ingestion, and are
gone from circulation 4–6 hours later [16]. In Germany, an
intravenous formulation of silibinin, Legalon-SIL (SIL), is licensed
for toxic mushroom poisoning [17]. SIL is a water-soluble version
of silibinin containing two succinate moieties covalently attached
to both silybin A and silybin B.
Recently SIL has been shown to potently reduce HCV RNA
levels in vivo when administered intravenously [18,19]. By
contrast, silymarin and silibinin do not appear to reduce HCV
RNA levels in patients when ingested orally [20,21], although they
both inhibit HCV infection in cell culture [11,12,15]. Since
silibinin and SIL are chemically different compounds, we
hypothesized that they exhibit differential effects. We therefore
compared the hepatoprotective profiles of the natural product
silibinin with SIL in assays that measure antiviral and anti-
inflammatory functions.
Materials and Methods
Subjects
Healthy subjects gave written informed consent to donate blood
through a University of Washington (UW) Institutional Review
Board-approved protocol; peripheral blood mononuclear cells
(PBMC) from these samples were used to generate the in vitro
results reported here.
Cells
Human hepatoma Huh7 and Huh7.5.1 cells were grown in
Huh7 medium as described [12]. BB7 and SGR7 cells are Huh7 cell
lines that contain subgenomic genotype 1b and 2a (JFH1) replicons
[11,22]. JFH-1 viral stock preparation, cell infection and titration
was performed as described [12]. PBMC were freshly isolated using
standard Ficoll-Hypaque centrifugation within 24 hours of veni-
puncture and immediately applied to the assays described below.
PBMC Proliferation Assay
PBMC were stimulated for 1 day at 37uC 5%CO2 with plate-
bound anti-CD3 (UCHT1, 10 mg/mL, BD Biosciences, San Jose,
CA) in RPMI 1640 medium supplemented with 10% human
serum (Gemini Bio-Products, Woodland, CA). Cellular prolifera-
tion was detected by 3H-thymidine incorporation into replicating
DNA was measured by adding 1 mCi to each replicate well of 105
PBMC for 24 hours before quantitative analysis using a
TopcountH Liquid Scintillation Counter (Perkin-Elmer, Waltham,
MA). Data are presented as mean counts per minute (cpm)
incorporated per condition tested. All experiments utilized three to
four replicates per condition.
Silibinin and SIL
Silibinin was purified from silymarin as described [23]. SIL was
kindly provided by Drs. Ulrich Mengs and Joe Villeaux (Rotta-
pharm/Madaus). Silibinin was solubilized in dimethylsulfoxide
(DMSO) for hepatocyte or methanol for PBMC experiments. SIL
was solubilized in PBS. Silibinin was an equimolar mixture of silybin
A and silybin B, and SIL was an equimolar mixture of disodium
disuccinyl silybin A and disodium disuccinyl silybin B (Figure 1).
Western Blot Analysis
Western blots were performed as described [12]. Actin and
NS5A were detected using commercial antiserum (Santa Cruz
Biotechnology, Santa Cruz, CA; BioDesign/Meridian Life
Science, Saco, ME). NS5A in JFH-1 infected cells was detected
with serum from patients infected with HCV genotype 2a.
HCV RNA Quantitation
HCV RNA was quantitated by real time RT-PCR, as
previously described [24]. Briefly, RNA was extracted from cells
following 72 hours of culture with SIL, silibinin, or PBS or DMSO
solvent controls using a commercial kit (Qiagen). Ten nanograms
of RNA were added to wells of a 384 well plate and the RT-PCR
reaction performed on an ABI HT7900 real time RT-PCR
machine. For each run, dilutions of BB7 or JFH-1 plasmid DNA
(precisely quantitated using the RiboGreen DNA quantitation kit
(Invitrogen)) ranging from 0–107 copies per well were run in
triplicate to generate a standard curve, which served as a reference
to calculate HCV RNA copy number based on the cycle threshold
(Ct).
Infectious Virus Production
Supernatants were harvested from cell cultures treated with SIL,
silibinin, or relevant solvent controls (PBS or DMSO), and filtered
through 10,000 molecular weight cutoff filters (UFC501096
Amicon Ultra-0.5, Ultracel-10 Membrane) to remove carry over
of SIL and silibinin. Filtered supernatants were serially diluted in
Huh7 media and used to infect naı̈ve Huh7.5.1 cells. Seventy-two
hours later, cells were fixed and the HCV core protein was
detected by immunofluorescence, using previously described
methods [15].
Membrane Fusion Assays
Lipid mixing between HCVpp and PC:chol:R18 liposomes was
monitored by fluorescent spectroscopy, as the dequenching of R18
[25]. In brief, R18-labeled liposomes were added to a well of a 37uC-
thermostable quartz microplate, containing 20 mL of HCVpp in
PBS pH 7.4 or PBS pH 7.4/0.5% DMSO, and incubated 2 min.
Lipid mixing was initiated by acidification to pH 5.0 with diluted
HCl, and recorded on a Tecan InfiniteH M1000 spectrofluorimeter
over a 15-min time period, at lexc = 560 nm and lem = 590 nm.
Maximal R18 dequenching was measured after the addition of 0.1%
Triton X-100 (final concentration) to the well. The same procedure
was used to follow HCVpp fusion in the presence of silibinin in
DMSO or SIL in PBS. After a 1-min incubation of HCVpp with
liposomes, silibinin (at 10.4, 20.7, 82.8 mM) or SIL (at 6.9, 13.8 or
55.2 mM) final concentration was added and incubated for 1 min,
and fusion initiated by acidification.
HCV NS5B Polymerase Assays
NS5BDC21 RNA polymerases C-terminally fused to a hexa-
histidine tag were expressed and purified as described [26]. RNA
polymerase activity was measured as poly-G synthesis from primed
poly-C templates as described (6). All reaction components except
[a32P]GTP and silibinin or SIL were preincubated for 30 minutes
at 30uC, then the reaction was started by adding [a32P]GTP plus
silibinin or SIL and was incubated for 1.5 hours at 30uC. Reaction
products were collected on nitrocellulose filters, the filters were
washed five times, air-dried, and subjected to liquid scintillation
counting to quantify the retained 32P-labeled RNA. All measure-
ments were done in triplicate and the IC50 values were calculated
with GraphPad Prism.
RNA Binding Assays
RNA binding by recombinant NS5B RNA polymerase was
determined using a filter-binding assay as previously described
SIL versus Silibinin in Hepatoprotection
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[26]. Briefly, the polymerase was incubated with radiolabeled
RNAs for 30 minutes on ice and the mixture was then passed
through Hybond-ECL nylon-backed nitrocellulose (GE Health-
care), and Hybond-N (GE Healthcare) membranes using a slot-
blot apparatus. The membranes were dried and retained
radioactivity was quantified with a Storm phosphorimager (GE
Healthcare).
Cytotoxicity Determinations
The toxicity of SIL on BB7 and Huh7.5.1 cells was determined
by measuring ATP levels using the ATPlite system (Perkin Elmer,
Boston, MA), as described [12].
PBMC viability was assessed by measuring cellular ATP levels
using the ATPlite kit (Perkin Elmer) and also by labeling with
Live/Dead Fixable Dead Cell Stain Kit (Violet viability dye,
Invitrogen/Molecular Probes, Carlsbad, CA) after culture/stimu-
lation for 24 hours and analysis using a Becton Dickinson FACS
Calibur (Puget Sound Blood Center, Seattle, WA) and FlowJo
software for Macintosh (version 6.3.3, Treestar, Inc., Ashland,
OR). ATPlite results are reported in relative light units (RLU).
Reporter Gene Assays
Endotoxin free plasmid DNA was purified (Plasmid Midi Kit +
Endofree buffers, QIAGEN, Valencia, CA), and was introduced
into cells with Lipofectamine 2000 as described [27]. 100 ng of the
pRDII-luciferase gene was transfected into cells in quadruplicate.
Eighteen hours later, cells were preincubated with SIL or silibinin
for 30 minutes before rhTNF-a (10 ng/ml; Sigma Aldrich, St.
Louis, MO) was added. Four hours later, luciferase activity was
measured on cell lysates using the Britelite Assay System (Perkin
Elmer). In separate experiments 50 ng/well of an IFN-B
promoter-luciferase plasmid was co-transfected with 25 ng of
IRF3-5D, a constitutively active mutant of IRF-3[28], and
24 hours later, cells were treated with silibinin or SIL for an
additional 24 hours before luciferase activity was measured.
Results are reported in relative light units (RLU).
Results
The chemical composition of silibinin and SIL are illustrated in
Figure 1. The preparations were compared on an equimolar basis
in all experiments.
Cytotoxicity Profile of SIL
We first determined the cytotoxicity profile of SIL, by
measuring cellular ATP levels, which is a sensitive marker for
cytotoxicity, using a fluorescence-based assay (please see Materials
and Methods). SIL was well tolerated by BB7 subgenomic replicon
(Figure 2A) and Huh7.5.1 cells (Figure 2B) over 500 mM.
Similarly, PBMC viability was maintained at high concentrations
of SIL, with only a 25% decrease in viability (measured as a
reduction in relative light units (RLU)) at a dose of 828 mM
(Figure 2C). This is strikingly different than silibinin, which is toxic
to BB7, Huh7.5.1, and PBMC above 80 mM [15]. Cytotoxicity
against PBMC was also evaluated by uptake of a viability dye and
no significant toxicity to SIL was noted through 828 mM (data not
shown).
Antiviral Effects of SIL and Silibinin: Effects on Fusion
During HCV entry into liver cells, the viral envelope fuses with
endosomal membranes to release the viral genome into cells [29].
We have recently shown that silymarin and other synthetic
antivirals block the fusion process [11,30]. We therefore tested
silibinin and SIL in a lipid mixing experiment. In this assay,
HCVpp are mixed with fluorescently-labeled liposomes, in the
presence or absence of silibinin or SIL. Mixing of viral envelope
lipids with liposomes, defined as the fluorescence dequenching of
the probe incorporated in the liposome membrane, is then
measured by spectrofluorimetry. Both mixtures inhibited fusion,
observed as a decrease in fluorescence recovery, in a dose-
dependent manner, with SIL being more potent (Figure 3A).
Indeed, SIL completely inhibited fusion at 55 mM, with an IC50 of
approximately 6 mM (Figure 3B). Note that DMSO, the solvent
into which silibinin is dissolved, did not affect fusion (data not
shown). The data suggest that silibinin and SIL can inhibit HCV
entry at the fusion stage.
Antiviral Effects of SIL and Silibinin: Effects on HCV
Polymerase
Figure 4A and Table 1 compare the ability of silibinin and SIL
to inhibit the standard BK genotype 1b NS5B RNA polymerase
and 4 patient-derived 1b isolates with a wide range of basal RNA
polymease activities [31] by SIL and silibinin. As described in the
Materials and Methods, the assay measures the ability of purified
Figure 1. Chemical structures of SIL and silibinin. See text for details.
doi:10.1371/journal.pone.0016464.g001
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NS5B proteins to incorporate 32P labeled GTP into a synthetic
RNA template. The inhibitory activity of silibinin against all 5
RdRps was weak and was similar to that of silymarin [11], with
IC50s ranging from 169 to .1000 mM. SIL inhibited RNA
synthesis by the RdRps more efficiently, as indicated by lower
IC50 values (40–85 mM).
To further investigate the difference in activity between SIL and
silibinin, the effect of these mixtures on the ability of purified
NS5B RNA polymerase to bind 32P-labeled RNA templates was
measured in a filter-binding assay. Figures 4B and 4C demon-
strates that SIL inhibited RNA binding by the polymerase at lower
concentration than they inhibited RNA polymerization, with
approximately 90% inhibition by 111 mM. In contrast, neither
silymarin nor SbN inhibited RNA binding strongly at these
concentrations. The data indicate that SIL was able to prevent
NS5B binding to RNA templates in vitro. However, as shown in
Table 1, the net inhibition of all polymerases when the drugs were
added after the RNA polymerase was allowed to bind to the
primer template was very limited because the inhibition plateaued
at 43–73% even at high drug concentrations. Together, these data
indicate that SIL may inhibit HCV replication in part by blocking
binding of the RNA polymerase to its template, but that direct
inhibition of the RNA polymerase activity is unlikely to be a major
contributor to its antiviral effect.
Antiviral Effects of SIL and Silibinin: Effects on HCV RNA
and Protein Expression in Replicon Cells and JFH-1
Infected Cells
Figure 5 shows the antiviral profiles of SIL (Figure 5A) and
silibinin (Figure 5B) against BB7, a subgenomic 1b replicon cell
line, and against JFH-1 infection of Huh7.5.1 cells. SIL inhibited
HCV RNA and protein expression in BB7 replicon cells above
25 mM. SIL inhibited JFH-1 RNA and protein expression at
higher concentrations of 138 and 414 mM. In contrast, silibinin
did not significantly inhibit HCV RNA and protein expression in
BB7 replicon cells, but inhibited JFH-1 RNA and protein
expression above 15 mM (Figure 5B and [11,15]). Furthermore,
neither SIL nor silibinin inhibited viral protein expression in
subgenomic JFH-1 replicon cell lines (Figure 5C). Thus, the
antiviral profile of silibinin is identical to silymarin [11], which
inhibits HCV infection but does not inhibit HCV replication in
non-infectious replicon cell lines. SIL inhibits genotype 1b non-
infectious replicons and JFH-1 infection, with stronger antiviral
activity against the genotype 1b replicon. Silibinin and SIL also
inhibited infectious progeny virus production, measured as a
decrease in infectivity titers (focus-forming units per milliliter) in
supernatants from infected cells (Figure 5D).
Effects of SIL and Silibinin on Inflammatory and Antiviral
Signaling
Silymarin suppresses inflammatory cytokine and chemokine
induction via blockade of NF-kB [11,12,13,15]. We therefore
compared the ability of SIL and silibinin to block NF-kB using a
luciferase reporter gene under control of the NF-kB promoter.
Figures 6A and 6B demonstrate that silibinin but not SIL blocked
TNF-a induced NF-kB transcription. Next, to examine the effect
of SIL and silibinin on innate antiviral signaling, we measure the
effect of the mixtures on IRF3-5D induced transcription of the
IFN-B promoter. IRF3-5D is a constitutively active mutant of
IRF-3 [28] which activates IFN-B transcription in absence of
additional stimuli. Silibinin but not SIL blocked IRF-3 activation
of the IFN-B promoter (Figures 6C and 6D). Thus, the two
mixtures differentially suppress inflammatory and antiviral signal-
ing pathways.
Anti-Inflammatory Effects of SIL and Silibinin on T Cells
Given its lack of ability to inhibit NF-kB in hepatocyte cultures,
we wondered whether SIL maintained the ability to inhibit PBMC
proliferation, as shown previously for silymarin [12,15]. SIL and
silibinin dose-dependently inhibited PBMC proliferation induced
by plate-bound anti-CD3 (Figure 7). The degree of inhibition was
similar for both mixtures, with IC50’s of 12.3 mM and 12.9 mM for
silibinin and SIL, respectively.
Figure 2. Cytotoxicity profile of SIL on BB7 subgenomic
replicon cells (A), Huh7.5.1 cells (B), and PBMC (C). Cells were
plated in quadruplicate in 96 well plates and the indicated concentra-
tions of SIL in PBS were added. Cells were incubated for 72 hours (for
BB7 and Huh7.5.1 cells) and 24 hours for PBMCs before ATP levels were
measured as described in the Materials and Methods. Fluorescence is
reported as relative light units (RLU).
doi:10.1371/journal.pone.0016464.g002
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Discussion
In the current study, we characterized the biological activities of
oral (natural, ie silibinin) and intravenous (semi-synthetic, ie SIL)
preparations from milk thistle on the HCV life cycle and
inflammatory cellular functions that collectively contribute to
development and progression of liver disease in hepatitis C. We
demonstrate for the first time that SIL and silibinin elicit very
different antiviral and anti-inflammatory actions in human liver
and T cell cultures. Both mixtures inhibited virus fusion potently
and NS5B RdRp activity weakly. SIL inhibited NS5B binding to
RNA, whereas silibinin did not. Silibinin did not inhibit HCV
RNA and protein expression from subgenomic genotype 1b or 2a
replicons, but it did inhibit JFH-1 infection. In contrast, SIL
inhibited 1b but not 2a subgenomic replicons and also inhibited
JFH-1 infection at much higher doses than required for RdRp
inhibition. Both silibinin and SIL inhibited progeny virus
production from JFH-1 infected cells. Silibinin but not SIL
inhibited innate inflammatory and antiviral signaling from NF-kB
and IFN-B promoters. Both SIL and silibinin suppressed T cell
proliferation to similar degrees. Overall, silibinin activity was
similar to silymarin in all assays tested [13,15], while SIL had a
Figure 3. Silibinin and SIL inhibit HCVpp-mediated fusion. Membrane fusion between HCVpp and R18-labeled liposomes was followed by
fluorescence spectroscopy with excitation and emission at 560 and 590 nm, respectively. Fluorescent liposomes (12.5 mM final lipid concentration)
were added to 20 ml of HCVpp in PBS pH 7.4 at 37uC, in the absence or presence of 5, 10 or 40 mg/ml of indicated compound, which corresponds to
6.9, 13.8 or 55 mM of SIL and 10.4, 20.7, and 82.8 mM of silibinin. After a 2 min-equilibration, lipid mixing was initiated by decreasing the pH to 5.0 with
diluted HCl, and R18 dequenching was recorded. Maximal fluorescence was obtained after addition of 0.1% final Triton X-100 to the cuvette. A, values
of the last min of fusion (final extent of fusion) were used to calculate the percentage of fusion in the presence of the drug, relative to 100% fusion in
the absence of drug. Results are expressed from the mean of 2 separate experiments. Compounds were added at 5 (black), 10 (dark grey) or 40 mg/ml
(light grey). B, fusion kinetics of HCVpp with liposomes, in the absence (black) or presence of three concentrations of SIL: blue, 5 mg/ml; red, 10 mg/ml
and green, 40 mg/ml.
doi:10.1371/journal.pone.0016464.g003
Figure 4. Effect of silibinin and SIL on HCV RdRp Activity and Binding to RNA. A, Effects of silibinin and SIL on RNA synthesis by the HCV
RdRp. Purified HCV subtype 1b RdRps from the reference isolate BK and 4 patient derived-isolates were preincubated with poly-C and G10, then [a
32P]GTP and varying concentrations of silibinin or SIL were added and the reactions were incubated to permit RNA synthesis. The 32P-labeled RNA
was collected on nitrocellulose filters and retained radioactivity was measured by scintillation counting. Solid black lines, filled symbols, and SbN
indicate silibinin-containing reactions; open symbols, dashed lines, and SIL indicate SIL containing reactions. Concentrations are in micromolar. B,
Example RNA binding assay measuring the effect of silymarin, SbN, and SIL on RNA binding by the HCV RNA polymerase. Purified RNA polymerase
from the reference strain BK was allowed to bind to a 32P-labeled RNA in the presence of varying concentrations of the drugs, the mixture was
passed through a nitrocellulose filter to collect protein:RNA complexes, the filter was washed, and retained RNA was detected by phosphorimage
analysis. C, Summary of 4 independent repeats of the RNA binding assays. All data are normalized to values obtained with the DMSO vehicle control,
and error bars represent the standard deviation of the measurements.
doi:10.1371/journal.pone.0016464.g004
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unique profile, requiring higher concentrations for antiviral
activity in the JFH-1 system and was devoid of anti-inflammatory
activity in hepatocyte cultures.
The effects of SIL and silibinin were tested against a widely used
HCV genotype 1b isolate, BK, plus four patient-derived isolates
with widely varying specific activities for RNA synthesis. Overall,
both SIL and silibinin could inhibit the RdRps, with SIL being
somewhat better than silibinin. However, inhibition plateaued at
moderate drug concentrations, leading to maximal inhibition
levels in most cases of only about 2–3 fold. The reasons for this
unusual inhibition pattern are unknown. What is clear, however, is
that SIL and silibinin do not shut down in vitro polymerase
activity like nucleoside analog drugs do. Even at high concentra-
tions of SIL or silibinin, the net RdRp activity is only marginally
suppressed. We therefore posit that inhibition of NS5B polymerase
elongation provides only a minor contribution to the log-fold
suppression of viremia seen in patients receiving intravenous SIL.
This conclusion is supported by the observation that in vitro HCV
RdRp activity does not appear to be limiting for viral production
in vivo, because no correlation was found between in vitro RNA
polymerase activity and serum HCV titer in the patients from
which the polymerases were derived [31].
Silibinin as well as Legalon-SIL are mixtures of two diastereo-
isomers, silybins A and B. These molecules are arranged around a
flavonoid skeleton, and their overall structure is relatively
hydrophobic. It is therefore possible that these molecules may
act, at least in part, by incorporating or partitioning in the
hydrophobic core of lipid membranes of both viruses and target
(cell) membranes, as shown for similar compounds [32,33]. This
might lead to the stabilization of membranes by both molecules,
which would in turn become less prone to fusion. This behavior
would be reminiscent of that of arbidol, a broad-spectrum antiviral
inhibiting HCV entry, membrane fusion and replication, as
recently described by our group ([30,34]; Teissier & Pécheur,
unpublished observations).
Table 1. Inhibition of NS5B RNA Dependent RNA Polymerase
(RdRp) Activity by SIL and silibinin (SbN).
RdRp Drug Max inhibition (%) IC50 (mM)
BK SIL 58.8 39.9
SbN 67.3 210.0
234 SIL 43.1 43.9
SbN 57.0 169.0
242 SIL 57.3 64.3
SbN 45.7 ,1000
245 SIL 49.5 84.9
SbN 58.8 359.0
103 SIL 72.8 40.2
SbN 69.3 354.0
Polymerase assays were conducted as described in the Materials and Methods.
doi:10.1371/journal.pone.0016464.t001
Figure 5. Antiviral Activity of SIL and silibinin. A, effect of SIL on HCV replication in genotype 1b subgenomic replicon cells (BB7) and JFH-1
infection of Huh7.5.1 cells. The top panels show HCV NS5A protein expression detected by western blot, while the lower graph depicts HCV RNA
levels determined by real time RT-PCR. Cells were treated with 0, 6.9, 27.6, 138, and 414 mM of SIL for 72 hours before protein and RNA isolations. B,
effect of silibinin on HCV replication in genotype 1b subgenomic replicon cells (BB7) and JFH-1 infection of Huh7.5.1 cells. Cells were treated with
DMSO, 15.5, 31.1, and 62.1 mM of silibinin for 72 hours before protein and RNA isolations. C, effects of SIL and silibinin on HCV replication in
subgenomic JFH-1 replicon cells. Cells were treated with 0, 6.9, 27.6, 138, and 414 mM of SIL or DMSO, 20.7, 41.4, and 82.8 mM of silibinin for 72 hours
before proteins were extracted and NS5A detected by western blot. D, effect of SIL and silibinin on progeny virus production. Huh7.5.1 cells were
treated with 20 mg/ml silibinin, 300 mg/ml SIL or DMSO and PBS controls immediately after 5 hours of adsorption with JFH-1 at an m.o.i. of 0.05.
Culture supernatants were harvested 72 hours later and carry over silibinin or SIL was removed by concentration through 10,000 molecular filters.
Supernatants were diluted 1:100 in Huh7 media and used to infect naı̈ve Huh7.5.1 cells in triplicate and immunofluorescent detection of HCV core
protein was performed. Foci were counted manually and used to calculate infectious virus yields expressed as focus forming units per milliliter (FFU/
ml). Error bars represent standard deviations of triplicate cultures.
doi:10.1371/journal.pone.0016464.g005
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SIL was as efficient as silymarin at inhibiting HCV-mediated
fusion, with IC50 of ca. 6 mM and 5 mM respectively (see also
[11]). Interestingly SIL displayed a much more potent inhibitory
effect on HCV fusion than silibinin (IC50 6 mM vs ca. 25 mM,
respectively). This indicates that silybins A and B by themselves are
at least as efficient at blocking fusion as is silymarin, the mixture of
multiple flavonolignans (including silibinin). However the chemical
formulation of these molecules appears to alter pharmacological
and antiviral activity, since SIL, the disuccinate form of silibinin,
appears to be a more potent antiviral in the clinic than silibinin.
Further studies are needed to determine if the chemical
composition of SIL enhances its interaction with membranes.
HCV infection induces inflammation via hepatocellular sensing
of virus by PRRs [35,36], induction of oxidative stress
[37,38,39,40,41,42], and induction of inflammatory cytokines
and chemokines [27]. Unfortunately, this response, which is
usually beneficial to the host, is deregulated in chronic hepatitis C
because the virus is not cleared. Inflammatory events such as T cell
infiltration of the liver, and release of inflammatory cytokines and
chemokines damage the liver via further induction of oxidative
stress. Perpetuation of this inflammatory cascade and immune cell
mediated liver damage is thought to induce subsequent fibrosis.
Thus, chronic hepatitis C may be thought of as a disease caused by
an inflammatory response gone awry [43,44,45,46,47]. In this
harsh environment, hepatocytes die and regenerate more
frequently. Since chronic inflammation is mechanistically involved
in the establishment of cancer [48], and in particular hepatocel-
lular carcinoma [49], the deregulated cellular responses are an
integral part of the complex processes that lead to HCV-induced
liver disease. We have shown that silymarin displays antioxidant,
anti-inflammatory, antiviral, and immunomodulatory properties
[12,13,50]. Therefore, we propose that silymarin elicits hepato-
protection by multiple actions that collectively reduce inflamma-
tion by several mechanisms including inhibition of NF-kB
signaling, T cell proliferation and inflammatory cytokine produc-
tion, and virus infection. Regarding anti-HCV effects, although
silymarin and purified flavonolignans can inhibit NS5B polymer-
ase activity, we propose that blockade of viral targets is not the
dominant antiviral mechanism. Instead, silymarin blockade of
cellular targets may confer antiviral effects by blocking virus entry,
HCV RNA and protein expression, and virus transmission
[11,12,15].
In summary, our data clearly demonstrate that silibinin and SIL
function in different ways to induce hepatoprotection. SIL has
shown antiviral efficacy during liver transplantation for end-stage
hepatitis C [19] and for prior non-responders to pegylated IFN
plus ribavirin therapy [18]. However, silymarin, silibinin, and SIL
have been shown to modulate the expression and activity of
various drug-metabolizing enzymes [51,52,53]. Given that much
higher plasma and presumably liver levels of silymarin flavono-
Figure 6. Silibinin but not SIL inhibits innate inflammatory and antiviral signaling. A, B, effect of silibinin and SIL on NF-kB dependent
transcription. Huh7 cells were transfected with an NF-kB responsive reporter plasmid (pRDII-luc) and twenty-four hours later, cells were pretreated
with the indicated doses of silibinin (A) or SIL (B). Cells were then treated with 10 ng/ml TNF-a and luciferase activity measured by Britelite assay
3.5 hours later. C, D, effect of silibinin and SIL on IRF-3 driven transcription from the IFN-B promoter. Huh7.5.1 cells were co-transfected with a
luciferase reporter plasmid under control of the IFN-B promoter and IRF-35D, a constitutively active mutant of IRF-3 [28]. Twenty-four hours later, cells
were pretreated with the indicated doses of silibinin (C) or SIL (D). Luciferase activity measured by Britelite assay 24 hours later. Fluorescence is
reported as relative light units (RLU). Error bars represent standard deviation from triplicate cultures.
doi:10.1371/journal.pone.0016464.g006
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lignans can now be achieved via oral [21] and intravenous [54]
dosing, careful considerations should be given to the routes of
administration, chemical composition, and possible interactions of
pharmaceuticals with silymarin-derived flavonolignans [55]. Our
studies suggest that future clinical and basic research studies of
specific silymarin components, including those that are chemically
modified, will be the key to understanding their clinical effects and
developing novel and effective natural product-derived medicines
for liver disease.
Acknowledgments
We thank Kimberly Hardy and Xiaohong Cheng for technical assistance.
Author Contributions
Conceived and designed the experiments: JW CM TNG NHO ET E-IP
JET SJP. Performed the experiments: JW CM TNG ET E-IP. Analyzed
the data: JW CM TNG NHO ET E-IP JET SJP. Contributed reagents/
materials/analysis tools: NHO E-IP JET SJP. Wrote the paper: SJP CM
NHO JET E-IP.
References
1. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP (2006) The
contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and
primary liver cancer worldwide. J Hepatol 45: 529–538.
2. Fried MW, Shiffman M, Sterling RK, Weinstein J, Crippin J, et al. (2000) A
multicenter, randomized trial of daily high-dose interferon-alfa 2b for the
treatment of chronic hepatitis c: pretreatment stratification by viral burden and
genotype. Am J Gastroenterol 95: 3225–3229.
3. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, et al. (2002)
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
N Engl J Med 347: 975–982.
Figure 7. SIL and silibinin dose-dependently inhibit T cell proliferation. For all assays, a single dose of silibinin or SIL was added at culture
initiation and compared to parallel cultures treated with a single dose of silibinin vehicle (MetOH) or media (control for SIL). Freshly isolated PBMC
were tested for proliferative responses to plate-bound anti-CD3 (10 mg/mL) stimulation measured using 3H-thymidine incorporation. A, PBMC
cultures treated with SIL at various doses (black bars) and the media control (white bar). Cells were also separately treated with silibinin control (gray
bar), and the corresponding methanol control (hatched bar). B, PBMC cultures were treated with silibinin at various doses (gray bars), or with
methanol solvent controls (hatched bars). Cells were also treated with silymarin as a positive control for inhibition of proliferation (bar with vertical
lines). Open bars represent proliferation of PBMC stimulated with anti-CD3 alone in media, which serves as the control for SIL treatment. Results are
shown as mean cpm incorporated. Error bars indicate 1 standard deviation among 3–4 replicates for each condition.
doi:10.1371/journal.pone.0016464.g007
SIL versus Silibinin in Hepatoprotection
PLoS ONE | www.plosone.org 8 January 2011 | Volume 6 | Issue 1 | e16464
4. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, et al.
(2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus
ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet
358: 958–965.
5. Kroll DJ, Shaw HS, Oberlies NH (2007) Milk thistle nomenclature: why it
matters in cancer research and pharmacokinetic studies. Integr Cancer Ther 6:
110–119.
6. Seeff LB, Curto TM, Szabo G, Everson GT, Bonkovsky HL, et al. (2008) Herbal
product use by persons enrolled in the hepatitis C Antiviral Long-Term
Treatment Against Cirrhosis (HALT-C) Trial. Hepatology 47: 605–612.
7. NCCAM (2003) Hepatitis C and Complementary and Alternative Medicine:
2003 Update. Research Report: National Center for Complementary and
Alternative Medicine. pp 2–20.
8. Mayer KE, Myers RP, Lee SS (2005) Silymarin treatment of viral hepatitis: a
systematic review. J Viral Hepat 12: 559–567.
9. Liu J, Manheimer E, Tsutani K, Gluud C (2003) Medicinal herbs for hepatitis C
virus infection: a Cochrane hepatobiliary systematic review of randomized trials.
Am J Gastroenterol 98: 538–544.
10. Melhem A, Stern M, Shibolet O, Israeli E, Ackerman Z, et al. (2005) Treatment
of chronic hepatitis C virus infection via antioxidants: results of a phase I clinical
trial. J Clin Gastroenterol 39: 737–742.
11. Wagoner J, Negash A, Kane OJ, Martinez LE, Nahmias Y, et al. (2010) Multiple
effects of silymarin on the hepatitis C virus lifecycle. Hepatology 51: 1912–1921.
12. Polyak SJ, Morishima C, Shuhart MC, Wang CC, Liu Y, et al. (2007) Inhibition
of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV
infection by standardized silymarin. Gastroenterology 132: 1925–1936.
13. Morishima C, Shuhart MC, Wang CC, Paschal DM, Apodaca MC, et al. (2010)
Silymarin Inhibits in Vitro T Cell Proliferation and Cytokine Production in
Hepatitis C Virus Infection. Gastroenterology.
14. Ahmed-Belkacem A, Ahnou N, Barbotte L, Wychowski C, Pallier C, et al. (2010)
Silibinin and Related Compounds Are Direct Inhibitors of Hepatitis C Virus
RNA-Dependent RNA Polymerase. Gastroenterology 138: 1112–1122.
15. Polyak SJ, Morishima C, Lohmann V, Pal S, Lee DY, et al. (2010) Identification
of hepatoprotective flavonolignans from silymarin. Proc Natl Acad Sci U S A
107: 5995–5999.
16. Wen Z, Dumas TE, Schrieber SJ, Hawke RL, Fried MW, et al. (2008)
Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin
flavonolignans in human plasma after oral administration of milk thistle extract.
Drug Metab Dispos 36: 65–72.
17. Cavalieri C (2007) Intravenous Milk Thistle Compound Used to Save Victims of
Poisonous Mushrooms. Herbalgram: American Botanical Council. 16 p.
18. Ferenci P, Scherzer TM, Kerschner H, Rutter K, Beinhardt S, et al. (2008)
Silibinin is a potent antiviral agent in patients with chronic hepatitis C not
responding to pegylated interferon/ribavirin therapy. Gastroenterology 135:
1561–1567.
19. Neumann UP, Biermer M, Eurich D, Neuhaus P, Berg T (2010) Successful
prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-
therapy. J Hepatol.
20. Falasca K, Ucciferri C, Mancino P, Vitacolonna E, De Tullio D, et al. (2008)
Treatment with silybin-vitamin E-phospholipid complex in patients with
hepatitis C infection. J Med Virol 80: 1900–1906.
21. Hawke RL, Schrieber SJ, Soule TA, Wen Z, Smith PC, et al. (2010) Silymarin
ascending multiple oral dosing phase I study in noncirrhotic patients with
chronic hepatitis C. J Clin Pharmacol 50: 434–449.
22. Blight KJ, Kolykhalov AA, Rice CM (2000) Efficient initiation of HCV RNA
replication in cell culture. Science 290: 1972–1974.
23. Graf TN, Wani MC, Agarwal R, Kroll DJ, Oberlies NH (2007) Gram-scale
purification of flavonolignan diastereoisomers from Silybum marianum (Milk
Thistle) extract in support of preclinical in vivo studies for prostate cancer
chemoprevention. Planta Med 73: 1495–1501.
24. Plumlee CR, Lazaro CA, Fausto N, Polyak SJ (2005) Effect of ethanol on innate
antiviral pathways and HCV replication in human liver cells. Virol J 2: 89.
25. Lavillette D, Bartosch B, Nourrisson D, Verney G, Cosset FL, et al. (2006)
Hepatitis C virus glycoproteins mediate low pH-dependent membrane fusion
with liposomes. J Biol Chem 281: 3909–3917.
26. Cannon NA, Donlin MJ, Mayes LM, Lyra AC, Di Bisceglie AM, et al. (2009)
Evidence for action of ribavirin through the hepatitis C virus RNA polymerase.
J Viral Hepat 16: 595–604.
27. Wagoner J, Austin M, Green J, Imaizumi T, Casola A, et al. (2007) Regulation
of CXCL-8 (interleukin-8) induction by double-stranded RNA signaling
pathways during hepatitis C virus infection. J Virol 81: 309–318.
28. Lin R, Mamane Y, Hiscott J (1999) Structural and functional analysis of
interferon regulatory factor 3: localization of the transactivation and auto-
inhibitory domains. Mol Cell Biol 19: 2465–2474.
29. Dubuisson J, Helle F, Cocquerel L (2008) Early steps of the hepatitis C virus life
cycle. Cell Microbiol 10: 821–827.
30. Pecheur EI, Lavillette D, Alcaras F, Molle J, Boriskin YS, et al. (2007)
Biochemical Mechanism of Hepatitis C Virus Inhibition by the Broad-Spectrum
Antiviral Arbidol. Biochemistry 46: 6050–6059.
31. Cao F, Donlin MJ, Turner K, Cheng X, Tavis JE (2010) Genetic and
biochemical diversity in the HCV NS5B RNA polymerase in the context of
interferon alpha plus ribavirin therapy. J Viral Hepat.
32. Chaudhuri S, Pahari B, Sengupta B, Sengupta PK (2010) Binding of the
bioflavonoid robinetin with model membranes and hemoglobin: Inhibition of
lipid peroxidation and protein glycosylation. J Photochem Photobiol B 98:
12–19.
33. Chaudhuri S, Pahari B, Sengupta PK (2009) Ground and excited state proton
transfer and antioxidant activity of 7-hydroxyflavone in model membranes:
absorption and fluorescence spectroscopic studies. Biophys Chem 139: 29–36.
34. Boriskin YS, Pecheur EI, Polyak SJ (2006) Arbidol: a broad-spectrum antiviral
that inhibits acute and chronic HCV infection. Virol J 3: 56.
35. Foy E, Li K, Sumpter R, Jr., Loo YM, Johnson CL, et al. (2005) Control of
antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible
gene-I signaling. Proc Natl Acad Sci U S A 102: 2986–2991.
36. Li K, Chen Z, Kato N, Gale M, Jr., Lemon SM (2005) Distinct poly(I-C) and
virus-activated signaling pathways leading to interferon-beta production in
hepatocytes. J Biol Chem 280: 16739–16747.
37. Qadri I, Iwahashi M, Capasso JM, Hopken MW, Flores S, et al. (2004) Induced
oxidative stress and activated expression of manganese superoxide dismutase
during hepatitis C virus replication: role of JNK, p38 MAPK and AP-1.
Biochem J 378: 919–928.
38. Lai MMC (2002) Hepatitis C Virus Proteins: Direct Link to Hepatic Oxidative
Stress, Steatosis, Carcinogenesis and More. Gastroenterology 122: 568–571.
39. Okuda M, Li K, Beard MR, Showalter LA, Scholle F, et al. (2002)
Mitochondrial injury, oxidative stress, and antioxidant gene expression are
induced by hepatitis C virus core protein. Gastroenterology 122: 366–375.
40. Gong G, Waris G, Tanveer R, Siddiqui A (2001) Human hepatitis C virus NS5A
protein alters intracellular calcium levels, induces oxidative stress, and activates
STAT-3 and NF-kappa B. Proc Natl Acad Sci U S A 98: 9599–9604.
41. Bureau C, Bernad J, Chaouche N, Orfila C, Beraud M, et al. (2001)
Nonstructural 3 protein of hepatitis C virus triggers an oxidative burst in
human monocytes via activation of NADPH oxidase. J Biol Chem 276:
23077–23083.
42. Vendemiale G, Grattagliano I, Portincasa P, Serviddio G, Palasciamo G, et al.
(2001) Oxidative stress in symptom-free HCV carriers: relation with ALT flare-
up. Eur J Clin Invest 31: 54–63.
43. Carr DJ, Tomanek L (2006) Herpes simplex virus and the chemokines that
mediate the inflammation. Curr Top Microbiol Immunol 303: 47–65.
44. Glass WG, Rosenberg HF, Murphy PM (2003) Chemokine regulation of
inflammation during acute viral infection. Curr Opin Allergy Clin Immunol 3:
467–473.
45. Mackay CR (2001) Chemokines: immunology’s high impact factors. Nat
Immunol 2: 95–101.
46. Melchjorsen J, Sorensen LN, Paludan SR (2003) Expression and function of
chemokines during viral infections: from molecular mechanisms to in vivo
function. J Leukoc Biol 74: 331–343.
47. Tripp RA, Oshansky C, Alvarez R (2005) Cytokines and respiratory syncytial
virus infection. Proc Am Thorac Soc 2: 147–149.
48. Moss SF, Blaser MJ (2005) Mechanisms of disease: Inflammation and the origins
of cancer. Nat Clin Pract Oncol 2: 90–97; quiz 91 p following 113.
49. Branda M, Wands JR (2006) Signal transduction cascades and hepatitis B and C
related hepatocellular carcinoma. Hepatology 43: 891–902.
50. Wagoner J, Negash A, Kane OJ, Martinez LE, Nahmias Y, et al. (2010) Multiple
Effects of Silymarin on the Hepatitis C Virus Lifecycle. Hepatology in press.
51. Kim CS, Choi SJ, Park CY, Li C, Choi JS (2010) Effects of silybinin on the
pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen in
rats. Anticancer Res 30: 79–85.
52. Brandon-Warner E, Sugg JA, Schrum LW, McKillop IH (2010) Silibinin
inhibits ethanol metabolism and ethanol-dependent cell proliferation in an in
vitro model of hepatocellular carcinoma. Cancer Lett 291: 120–129.
53. Wu JW, Lin LC, Tsai TH (2009) Drug-drug interactions of silymarin on the
perspective of pharmacokinetics. J Ethnopharmacol 121: 185–193.
54. Wu JW, Lin LC, Hung SC, Chi CW, Tsai TH (2007) Analysis of silibinin in rat
plasma and bile for hepatobiliary excretion and oral bioavailability application.
J Pharm Biomed Anal 45: 635–641.
55. Brantley SJ, Oberlies NH, Kroll DJ, Paine MF (2010) Two flavonolignans from
milk thistle (Silybum marianum) inhibit CYP2C9-mediated warfarin metabolism
at clinically achievable concentrations. J Pharmacol Exp Ther 332: 1081–1087.
SIL versus Silibinin in Hepatoprotection
PLoS ONE | www.plosone.org 9 January 2011 | Volume 6 | Issue 1 | e16464
